Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for TARA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 142.49M
March 31, 2026 135.79M
December 31, 2025 155.55M
September 30, 2025 132.67M
June 30, 2025 122.22M
March 31, 2025 124.36M
December 31, 2024 170.29M
September 30, 2024 81.50M
June 30, 2024 89.58M
March 31, 2024 55.22M
December 31, 2023 65.58M
September 30, 2023 74.03M
June 30, 2023 80.36M
March 31, 2023 86.61M
December 31, 2022 84.37M
September 30, 2022 96.32M
June 30, 2022 98.46M
March 31, 2022 87.59M
December 31, 2021 91.23M
September 30, 2021 93.76M
June 30, 2021 84.67M
March 31, 2021 84.40M
December 31, 2020 168.65M
September 30, 2020 165.95M
June 30, 2020 30.02M
Date Value
March 31, 2020 36.12M
December 31, 2019 0.564M
September 30, 2019 9.371M
June 30, 2019 10.81M
March 31, 2019 16.76M
December 31, 2018 21.87M
September 30, 2018 26.21M
June 30, 2018 26.45M
March 31, 2018 36.82M
December 31, 2017 42.14M
September 30, 2017 47.43M
June 30, 2017 31.74M
March 31, 2017 34.13M
December 31, 2016 41.32M
September 30, 2016 46.97M
June 30, 2016 53.67M
March 31, 2016 59.39M
December 31, 2015 65.26M
September 30, 2015 70.55M
June 30, 2015 74.74M
March 31, 2015 79.52M
December 31, 2014 83.60M
September 30, 2014 21.72M
June 30, 2014 25.46M
March 31, 2014 3.625M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
NovelStem International Corp. 0.0562M
Brainstorm Cell Therapeutics, Inc. 0.022M
Summit Therapeutics, Inc. 691.00M
Kezar Life Sciences, Inc. 66.23M
Clene, Inc. 9.671M